Trial Profile

Pivotal phase III trial of oxycodone controlled release [Rexista] in patients with chronic low back pain

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Oxycodone (Primary)
Indications Back pain
Focus Registrational; Therapeutic Use

Most Recent Events

09 Oct 2015 According to Intellipharmaceutics media release, the company plans to complete the filing of NDA for Rexista Oxycodone XR (Abuse Deterrent oxycodone hydrochloride) extended release tablets with the FDA in the first half of 2016.
30 Mar 2015 Intellipharmaceutics recently filed an IND to the FDA for Rexista, according to a media release.
17 Jul 2013 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com